Controls serum phosphorus. ANDA 212970, held by Epic Pharma LLC. Sevelamer Carbonate.
As of Nov 16, 2026, ANDA 212970 (Sevelamer Carbonate), held by Epic Pharma LLC, was first approved by FDA on Apr 9, 2020, with 1 approved supplement and 0 published complete response letters.
Sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 9, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sevelamer Carbonate800MG · tablet;oral | Sevelamer Carbonate | Discontinued |
| Jan 4, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 9, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters